Business
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis
JERSEY CITY, N.J., July 07, 2025--Organon's steroid-free VTAMA (tapinarof) cream 1%, granted strong recommendation in American Academy of Dermatology guidelines for atopic dermatitis.
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2100,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/a8db8d1515fa796f2109ac0897b08b32"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PITC6Az00VX4JUlWfcq4Yg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a8db8d1515fa796f2109ac0897b08b32","width":960,"height":144},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/c51p8fsYx7KQVDtvu0FOUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a8db8d1515fa796f2109ac0897b08b32","width":1200,"height":180}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The American Academy of Dermatology (AAD) provides a strong evidence-based recommendation for the use of VTAMA cream in adults with moderate to severe atopic dermatitis (AD), the most common form of eczema.","length":206,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Recommendation reflects VTAMA cream’s proven efficacy, safety, and tolerability as a steroid-free, topical aryl hydrocarbon receptor agonist.","length":141,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"AD impacts 26 million people in the United States, 16.5 million of which are adults.","length":84,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":431,"olType":false},{"type":"text","content":"JERSEY CITY, N.J., July 07, 2025--(BUSINESS WIRE)--Organon (NYSE: OGN), a global independent healthcare company with a focus on women’s health, today announced that VTAMA® (tapinarof) cream, 1%, was granted a strong recommendation by the American Academy of Dermatology (AAD) in their 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis (AD). The recommendation underscores VTAMA cream as an effective, steroid-free option for daily disease management, with no label warnings or precautions, no contraindications, and no restrictions on duration of use or percentage of body surface area affected. In AD, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal ...